LGM Pharma, a prominent provider of customized API and CDMO services throughout the drug product lifecycle, has unveiled major upgrades to its capabilities. This includes a 50% expansion and a substantial investment of over $2 million in its Analytical Testing Services (ATS) division, along with the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio. These strategic improvements not only enhance internal capacity for growth but also offer customers a more streamlined, efficient, and comprehensive solution for their manufacturing requirements
LGM Pharma, known for its comprehensive API and CDMO solutions, has expanded its capabilities in standalone Analytical Testing Services (ATS) and added new suppository manufacturing capabilities to its portfolio.
The company’s ATS division offers a wide range of analytical testing services for small-molecule drug substances and products, catering to both large pharmaceutical firms and startups. This includes method development, validation services, and stability testing using real-time and accelerated studies. Equipped with state-of-the-art instrumentation like ICP-MS and ICP-OES, LGM Pharma’s analytical laboratories in Irvine, California, surpass industry standards.
Prasad Raje, Ph.D., CEO of LGM Pharma, highlighted how standalone ATS enhances their ability to support pharmaceutical partners with tailored services, facilitating faster market entry and long-term success.
Meanwhile, LGM Pharma is expanding its suppository manufacturing capabilities in Rosenburg, Texas, in response to the growing demand for suppository drug delivery systems, especially in women’s health products. These systems offer precise drug release kinetics and are ideal for patients with swallowing difficulties or chronic conditions.
Ian Gibson, EVP of Operations at LGM Pharma, emphasized the company’s commitment to providing specialized capabilities to meet the evolving needs of the pharmaceutical industry, including advanced suppository formulation and manufacturing expertise.
